Protagonist Therapeutics: Peptide Therapies Drive Record Revenue with ICOTYDE Approval
Reading Time: 3 minutes
Protagonist Therapeutics focuses on peptide-based therapeutics with revenue participation through strategic partnerships with leading pharmaceutical companies. The FDA approval of ICOTYDE in March and the exercise of an opt-out option for Rusfertide generated significant milestone payments from Takeda and J&J. The 2nd quarter provides a revenue boost with milestone payments. Goldman Sachs points to the great potential of the drug candidate PN-881, setting a price target of $186 (Buy). Protagonist Therapeutics (PTGX) has established...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
